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Abstract

Antibiotics are one of the most important developments in medicine, and their
ability to prevent and control infections has had a major impact in clinical medicine.
However, the past three decades have shown an increase in multidrug-resistant organisms
(MDROs) in both hospital patients and in the community, decreasing our ability to
successfully control infection. Complicating the depletion of effective antimicrobials is
the fact that, in the last 10 years, there has also been a decrease in the development of
new antibacterial agents. Resistant infections have resulted in increased morbidity and
mortality, with a consequential increase in healthcare costs. The utilization of
antimicrobial stewardship strategies in hospitals has been shown to decrease
antimicrobial use, decrease antimicrobial resistance patterns, decrease the development of
secondary infections, reduce adverse medication effects, and consequently decrease
healthcare costs. In 2007, the Infectious Diseases Society of America and the Society for
Healthcare Epidemiology of America published the Guidelines for Developing an
Institutional Program to Enhance Antimicrobial Stewardship, encouraging hospitals to
implement antimicrobial stewardship programs and presenting a blueprint for their
development. After the Guidelines were published, several surveys of current
antimicrobial stewardship practices ensued, including ones specific to certain states, ones
geared towards the members of certain infectious disease professional societies, and even
one attempting to assess antimicrobial stewardship practices nationally. For the most
part, these surveys have found fairly widespread implementation of antimicrobial
stewardship strategies, even in the absence of formal antimicrobial stewardship programs.
However, these surveys have also found that barriers to implementation of stewardship
iii

programs are common. Because the Western United States has been relatively underrepresented in these surveys, this project aimed to determine to what degree hospitals in
western states are engaging in stewardship strategies. Additional aims were to further
elucidate the barriers to antimicrobial stewardship, and to identify factors associated with
the number of antimicrobial stewardship strategies in use in a facility. A web-based
antimicrobial stewardship survey was disseminated via email to pharmacy directors,
medical directors, infection control professionals, and other healthcare professionals at
general acute care and critical access hospitals in 19 states. Responses (n=105) were
summarized using descriptive statistics and univariate analyses of associations between
survey respondents and hospital characteristics and the reported usage of the various
antimicrobial stewardship strategies. Results demonstrated the widespread use of
antimicrobial stewardship strategies, even in spite of simultaneous reports of barriers to
the establishment of formal antimicrobial stewardship programs. A multivariate model
was developed via multiple linear regression, which identified six predictors of the
number of antimicrobial stewardship strategies in use at a hospital. This model can be
utilized to guide the further development of antimicrobial stewardship in facilities that are
struggling with MDROs.
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Introduction
Antibiotics are one of the most important developments in medicine, and their
ability to prevent and control infections has had a major impact in surgery, transplant
medicine, oncology, and intensive care medicine (Society for Healthcare Epidemiology
of America [SHEA] et al., 2012). The use of antimicrobials began in the 1930s and
1940s with the introduction of sulfonamides, penicillin, and streptomycin (SHEA et al.,
2012). From the 1950s onward, a large number of natural and synthetic antimicrobial
agents became available (SHEA et al., 2012). However, gradually, bacteria evolved
strategies of resistance to these antimicrobials, and the antibiotics became less effective
(SHEA et al., 2012). The past three decades have witnessed an increase in multidrugresistant organisms (MDROs) in patients admitted to hospitals and in the community.
Examples include the spread of methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant enterococci (VRE) among patients in healthcare settings, as well as
carbapenemase-producing Klebsiella pneumoniae and other carbapenem-resistant
Enterobacteriaceae spp. (CRE) (SHEA et al., 2012). In fact, the term “panresistant” is
unfortunately not too strong of a description for some of the most recent pathogens that
have been isolated (SHEA et al., 2012). As the SHEA, the Infectious Diseases Society of
America (IDSA), and the Pediatric Infectious Diseases Society (PIDS) state in their joint
Policy Statement, “It is ironic that in the twenty-first century we are encountering
bacterial infections for which we have no treatment” (2012).
Complicating the depletion of effective antimicrobials is the fact that, in the last
10 years, there has also been a decrease in the development of new antibacterial agents
(Boucher et al., 2009), compromising our ability to treat infectious diseases (SHEA et al.,
2012). Resistant infections have resulted in increased morbidity and mortality, with a
1

consequential increase in healthcare costs (Cosgrove et al., 2002; Cosgrove et al.,
2003a&b; DiazGranados et al., 2005). The major professional infectious disease
societies have advocated a multifaceted approach to prevent and control the emergence of
antimicrobial-resistant organisms (SHEA et al., 2012). This recommended approach
includes ensuring that proper therapeutic agents are available, that rapid and reliable
diagnostics are available to detect specific pathogens and to determine their antimicrobial
susceptibilities, and that antimicrobial stewardship programs are promoted robustly
(SHEA et al., 2012).
Although each professional society and healthcare facility often has its own
definition of antimicrobial stewardship, the Policy Statement authored by SHEA, IDSA,
and PIDS defines antimicrobial stewardship as the “coordinated interventions designed to
improve and measure the appropriate use of antimicrobial agents by promoting the
selection of the optimal antimicrobial drug regimen including dosing, duration of therapy,
and route of administration” (2012). The justification for antimicrobial stewardship
programs rests on numerous studies that have demonstrated that antimicrobial therapy
increases the risk of acquiring resistant organisms (Lautenbach et al., 2002; Paterson et
al., 2004; Weber et al., 2003). This is especially troubling, given the fact that the overuse
and inappropriate use of antimicrobials has also been reported in the literature (Dellit et
al., 2007). Optimizing antimicrobial use should minimize antimicrobial resistance (Drew
et al., 2009), as well as achieve the best clinical outcome and minimize adverse events
(SHEA et al., 2012). Indeed, it has been reported that the implementation of
antimicrobial stewardship strategies in acute care hospitals decreases antimicrobial use
(by 22-36%), antimicrobial resistance patterns, development of secondary infections, and
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adverse medication effects, consequently decreasing healthcare costs in hospital settings
by $200,000 to $900,000 annually (Bal et al., 2011; Drew et al., 2009; Goff et al., 2011;
Ohl et al., 2011; Pope et al., 2009).
The goals of antimicrobial stewardship are to improve clinical outcomes,
minimize unintended consequences of antimicrobial use (such as adverse events and the
emergence of resistance), and reduce healthcare costs (Dellit et al., 2007; Drew et al.,
2009). In 2007, the IDSA and SHEA published guidelines on the development of
antimicrobial stewardship programs (Dellit et al., 2007). These guidelines recommend
combining effective antimicrobial stewardship with a comprehensive infection control
program to limit the emergence and transmission of antimicrobial-resistant bacteria
(Dellit et al., 2007). The Guidelines for Developing an Institutional Program to Enhance
Antimicrobial Stewardship encourage hospitals to implement antimicrobial stewardship
programs and present a blueprint for their development (Dellit et al., 2007).
As far as the antimicrobial stewardship team and administrative support are
concerned, the Guidelines recommend that core members of the multidisciplinary
antimicrobial stewardship team include an infectious diseases (ID) physician and a
clinical pharmacist with infectious diseases (ID) training, with the inclusion of a clinical
microbiologist, an information systems specialist, an infection control professional, and
hospital epidemiologist being optimal. The Guidelines also recommend collaboration
between the antimicrobial stewardship team, hospital infection control, and pharmacy and
therapeutics committees. The support and collaboration of hospital administration,
medical staff leadership, and local providers in the development and maintenance of
antimicrobial stewardship programs is also stressed by the Guidelines, and the
3

antimicrobial stewardship team leaders should negotiate with hospital administration to
obtain adequate authority, compensation, and expected outcomes for the program.
As for the elements or strategies recommended by the Guidelines, they include
both active and supplemental antimicrobial stewardship strategies. The active
antimicrobial stewardship strategies include prospective audit with intervention and
feedback, and formulary restriction/ preauthorization requirements for specific
antimicrobial agents. Recommended supplemental antimicrobial stewardship strategies
include education of prescribers, evidence-based guidelines and clinical pathways,
antimicrobial cycling with scheduled antimicrobial switch, antimicrobial order forms,
combination therapy, streamlining or de-escalation of therapy, dose optimization, and
conversion from parenteral to oral therapy as soon as possible. Other supports that are
recommended by the Guidelines include information technologies, such as electronic
medical records (EMRs), computerized physician order entry (CPOE), clinical decision
support, and computer-based surveillance, as well as microbiology laboratory assistance,
such as patient-specific culture and susceptibility data, surveillance of resistant
organisms, and molecular epidemiologic investigation of outbreaks.
To measure the degree of success of antimicrobial stewardship efforts, the
Guidelines recommend monitoring process and outcome variables, where the process
variables would include the degree to which antimicrobial use changed, and the outcome
variables would include reduction in resistance, decreased infection rates, and lowered
costs as a result of the process change.
The 2012 Policy Statement on Antimicrobial Stewardship by SHEA, IDSA, and
PIDS strongly encourages the Centers for Medicare and Medicaid Services (CMS) to
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require healthcare institutions to develop stewardship programs (SHEA et al., 2012).
Public reporting on healthcare-associated infections (HAIs) in healthcare settings is
increasingly being mandated by accrediting organizations, insurance companies, and
legislative entities (Drew et al., 2009; Trivedi et al., 2013). For example, California
Senate Bill (SB) 739 (Health and Safety Code §§ 1288.5–1288.9, 2006) established the
California Department of Public Health HAI program to conduct surveillance,
prevention, and public reporting of HAIs in general acute care hospitals in California. In
2008, SB 739 mandated that all general acute care hospitals develop processes for
evaluating the judicious use of antibiotics and monitor results using appropriate quality
improvement committees, thus providing an incentive for hospital administrators to
establish and direct resources toward active antimicrobial stewardship programs (Drew et
al., 2009; Trivedi et al., 2013). Currently, California is the only U.S. state with this type
of legislation. Perhaps of greatest concern for hospital administrators are recent payment
rules from CMS, where hospitals will lose a portion of their reimbursement when certain
preventable healthcare-associated infections occur (Drew et al., 2009).
After the Guidelines were published, surveys of antimicrobial stewardship
practices ensued by researchers in the United States, including two surveys specific to a
particular state (Abbo et al., 2013; Trivedi et al., 2013), one survey geared towards the
members of certain professional societies (Pope et al., 2009), and even an attempt to
capture the prevalence of antimicrobial stewardship practices nationally (Doron et al.,
2013). Response rates from these surveys ranged from 7% to 53%, yielding sample sizes
from 82 to 406 respondents (Abbo, et al., 2013; Doron, et al., 2013; Pope, et al., 2009;
Trivedi et al., 2013). The percentage of respondents that reported having an
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antimicrobial stewardship program at their facility averaged around 50%, but 75%-96%
of respondents reported the use of at least one antimicrobial stewardship strategy, with or
without having a formal program in place (Doron, et al., 2013; Pope, et al., 2009; Trivedi
et al., 2013).
The most commonly utilized antimicrobial stewardship strategies included
prospective monitoring of antimicrobial prescribing, formulary restriction, antibiograms
(i.e., the measurement and tracking of antimicrobial resistance), and automatic antibiotic
stop orders (Pope et al., 2009). Factors that have been found to be significantly
associated with the presence of an antimicrobial stewardship program include having an
infectious disease consultation service (Doron, et al., 2013) and having an infectious
disease pharmacist (Doron, et al., 2013). Barriers to antimicrobial stewardship have
included staffing issues (Pope et al., 2009; Trivedi et al., 2013), lack of funding (Trivedi
et al., 2013), higher-priority clinical initiatives (Pope et al., 2009), opposition from
prescribers (Pope, et al., 2009), and resistance from hospital administration (Pope, et al.,
2009). The Western U.S. has been relatively under-represented in these previous
antimicrobial stewardship practice surveys.
The aims of the present study were to assess both the current antimicrobial
stewardship practices and the barriers to antimicrobial stewardship in general acute care
and critical access hospitals in an under-represented portion of the United States. This
study also determined what percentage of hospitals are engaging in stewardship
strategies, elucidated the barriers faced by antimicrobial stewardship programs, and
identified factors associated with the number of antimicrobial stewardship strategies in
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use at a facility. In addition, the following research questions and hypotheses were
addressed.
Research questions
1. What percentage of hospitals in the surveyed states/regions are engaging in
antimicrobial stewardship strategies?
2. Which strategies and techniques are being employed in antimicrobial stewardship
efforts in hospitals in the surveyed states/regions?
3. What are the barriers to the overall success of antimicrobial stewardship efforts in
hospitals in the surveyed states/regions?
4. What factors are associated with the number of antimicrobial strategies
implemented in hospitals in the surveyed states/regions?
Hypothesis #1
Ho: The percentage of hospitals engaging in at least one antimicrobial
stewardship strategy is equal among the surveyed states/regions.
Ha: The percentage of hospitals engaging in at least one antimicrobial
stewardship strategy differs between the surveyed states/regions.
This hypothesis was tested using univariate analysis of variance (ANOVA) to determine
if the proportion of hospitals engaging in at least one stewardship strategy (continuous
outcome variable) differed by surveyed state or region (categorical predictor variable).
Mean differences were compared between the states/regions, and post‐hoc analyses were
conducted when statistically significant differences between states/regions occurred.
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Hypothesis #2
Ho: The strategies being employed in antimicrobial stewardship efforts are the
same across the surveyed states/regions.
Ha: The strategies being employed in antimicrobial stewardship efforts differ
between the surveyed states/regions.
This hypothesis was analyzed using univariate analysis of variance to determine if the
frequency of use of each antimicrobial stewardship strategy (continuous outcome
variable) is associated with the surveyed state/region (categorical predictor variable).
Mean differences were compared between the states/regions, and post‐hoc analyses were
conducted when statistically significant differences between states/regions occurred.

Hypothesis #3
Ho: The barriers to the success of antimicrobial stewardship efforts are the same
across the surveyed states/regions.
Ha: The barriers to the success of antimicrobial stewardship efforts differ
between the surveyed states/regions.
This hypothesis was tested using univariate analysis of variance to compare the frequency
of each barrier (continuous outcome variable) and surveyed state/region (categorical
predictor variable). Mean differences were compared between the states/regions, and
post‐hoc analyses were conducted when statistically significant differences between
states/regions occurred.
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Hypothesis #4
Ho: No factors are associated with the number of antimicrobial stewardship
strategies implemented.
Ha: There is at least one factor associated with the number of antimicrobial
stewardship strategies implemented.
This hypothesis was tested using multiple linear regression analysis to determine how
much variance in the number of stewardship strategies implemented (continuous outcome
variable) were accounted for by the linear combination of various continuous and
dichotomous predictor variables (e.g., surveyed state/region, hospital type, hospital size,
presence/absence of infectious disease consultation service, etc.).

Methods
Survey development
The present survey (Appendix A) was modeled after that created by Doron et al.,
2013, for the national assessment of the prevalence of antimicrobial stewardship practices
(Appendix B). The revised survey for the present study collected information on hospital
characteristics such as size, classification, and rurality, the presence of information
technologies and microbiology laboratory support, the presence of a formal antimicrobial
stewardship program, which personnel are on the antimicrobial stewardship team, the
presence of an infectious disease consultation service and/or fellowship program,
utilization of various antimicrobial strategies, barriers to implementation, and the process
and outcome measures used. Perceived degree of success from the use of antimicrobial
stewardship strategies was also ascertained, as well as the identification of the most
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concerning resistant organisms for each facility. Unlike the previous surveys in the
literature (Pope et al., 2009; Abbo et al., 2013; Doron et al., 2013; Trivedi et al., 2013),
definitions of each antimicrobial stewardship strategy and “antimicrobial stewardship
program” were provided in the present survey. This study qualified for exempt status
from the University of Nevada, Las Vegas (UNLV) Institutional Review Board, as had
been the case for previous surveys of this nature in the literature (Doron et al., 2013;
Trivedi et al., 2013).
Survey distribution
A link to the survey was created using Qualtrics (www.qualtrics.com), and the
survey link was disseminated through multiple waves of emails, with responses collected
over a period of 7 weeks (from January 16, 2014, through March 7, 2014). Several
strategies were utilized to disseminate the survey link to relevant audiences. One initial
strategy was the involvement of the HAI (Healthcare Associated Infection) staff members
of the CMS Quality Improvement Organizations (QIOs) in Alaska, Colorado, Hawaii,
Kansas, Montana, Nebraska, New Mexico, Nevada, South Dakota, Utah, and Wyoming
(Appendix C), to disseminate the survey link via their email lists of acute care and critical
access hospitals in their particular state. Another strategy was to target and message
relevant SHEA and Association for Professionals in Infection Control and Epidemiology
(APIC) members via membership directories (Appendix D), and the representation of the
additional western states of Arizona, California, Idaho, North Dakota, Oklahoma,
Oregon, Texas, and Washington were added to the sample with this strategy.
Participation was voluntary, and various communications, such as reminders via
email and during a webinar presentation by a Centers for Disease Control and Prevention
10

(CDC) representative, were utilized to encourage participation. Additionally, it was
announced in the initial messages to potential respondents that those who completed the
survey would receive a compilation of potentially useful antimicrobial stewardship
literature, as well as aggregated survey results, if they gave their contact information,
which was optional. Survey instructions specified that a single survey should be filled
out by one professional (e.g., pharmacy director, medical director, infectious diseases
professional, or other professional with knowledge of antimicrobial use) at each hospital.
Data analysis
Facilities were de-identified, and results were aggregated by state. Respondent
personal identifiers were only used for response clarification and the distribution of
promised antimicrobial stewardship literature and survey results. Responses were
summarized using descriptive statistics. Univariate analyses of associations between
hospital characteristics and the reported number of antimicrobial stewardship strategies
used were determined using t-tests, analyses of variance (ANOVAs), and
Pearson/Spearman correlations. Factors that were significant, with a p-value of less than
0.1, in the univariate analyses were included in the process of building the multivariate
model, which was analyzed using multiple linear regression (forward method). All
statistical analyses were performed using SPSS (v. 22).

Results
Description of sample
Of approximately 1000 to 1200 hospital representatives contacted (it is uncertain
of the number contacted via each QIO’s emailing efforts), there were 110 total hospitals
represented in the survey responses, an estimated response rate of about 9 to 11%. Five
11

responses were from non-Western states and were excluded from analyses, leaving a total
number of 105 responses. Respondents represented 17 out of the 19 states targeted for
this project; only Kansas and New Mexico were not represented. The HAI QIO staff
member for Kansas had requested that Kansas hospitals not be approached for this
survey, because the Kansas QIO was concurrently conducting its own antimicrobial
stewardship survey. California, Nevada, and Wyoming were the most represented states
in the sample at 21.9%, 18.1%, and 11.4%, respectively. The representativeness of the
sample was determined via comparison of the number of hospitals per state in the sample
(n=105) to the number of total hospitals per state in the population (n=1639), which was
obtained from the CMS Hospital Compare website
(https://data.medicare.gov/data/hospital-compare; last updated 2/26/14). The sample
represented 6.4% of the overall number of hospitals in the surveyed states. Further
details regarding the states represented are included in Table 1 and Figure 1.
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Table 1. Number/percent/representativeness of survey respondents, by state.
Sample (n=105)
State
CA
NV
WY
TX
NE
UT
CO
AZ
MT
ND
OK
OR
WA
SD
AK
HI
ID
NM

# Hospitals
23
19
12
9
8
6
5
3
3
3
3
3
3
2
1
1
1
0

% of
Sample
21.9%
18.1%
11.4%
8.6%
7.6%
5.7%
4.8%
2.9%
2.9%
2.9%
2.9%
2.9%
2.9%
1.9%
1.0%
1.0%
1.0%
0.0%

TOTALS

105

100.0%

3

Population (n=1639)
% Represented
# Hospitals
in Sample
348
6.6%
36
52.8%
29
41.4%
380
2.4%
91
8.8%
45
13.3%
75
6.7%
78
3.8%
58
5.2%
45
6.7%
127
2.4%
60
5.0%
91
3.3%
55
3.6%
21
4.8%
17
5.9%
41
2.4%
42
0.0%
1639

6.4%

3
3

1

3

2
6

23

12

19

8
5

0
3

3

0
9
1
1

Figure 1. Geographic distribution of survey respondents, by state.
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Since multiple states had low numbers of respondents, it was deemed necessary to group
the states into larger units for statistical testing, and the standard U.S. Federal Regions
were used for this purpose (http://en/wikipedia.org/wiki/File:USFederalRegions.svg).
Table 2 and Figure 2 provide information similar to Table 1 and Figure 1, but with
respect to Federal Regions. Two of the regions, VI and VII, contain several states that
were not targeted for this survey and, thus, are not represented in the sample.

Table 2. Number/percent/representativeness of survey respondents, by region.
Sample (n=105)
Population (n=2195)
Region Number Percent # Hospitals % Represented
VI
12
11.4%
748
1.6%
VII
8
7.6%
448
1.8%
VIII
31
29.5%
307
10.1%
IX
46
43.8%
479
9.6%
X
8
7.6%
213
3.8%
TOTALS
105
100.0%
2195
4.8%
Region VI: AR*, LA*, OK, NM, TX
Region VII: IA*, MO*, KS*, NE
Region VIII: CO, MT, ND, SD, UT, WY
Region IX: AZ, CA, HI, NV
Region X: AK, ID, OR, WA
*States not approached with survey link

14

8

31

46

6

8

12

Figure 2. Geographic distribution of survey respondents, by region.

A further characterization of survey respondent and hospital characteristics can be found
in Appendix E. The majority of survey respondents were infection control professionals
(57.1%), followed by pharmacy directors, infectious disease pharmacists, and other
pharmacists (24.8% combined), infectious diseases physicians and medical directors
(13.3% combined), and other disciplines such as hospital epidemiologists and quality
directors (4.8%). Of note was the representation of various hospital classifications in the
sample. Although general acute care hospitals (GACHs) represented 59.0% of the
sample, rural/critical access hospitals (CAHs) represented 27.6%, and specialty hospitals
represented 9.5%. Regarding hospital characteristics, there was a good balance of
hospitals that were part of multi-hospital healthcare systems (59.0%) versus independent
hospitals (41.0%). There was also a good representation of proprietary (30.5%) versus
not-for-profit hospitals (68.6%), as well as teaching (47.6%) versus non-teaching
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hospitals (52.4%). The number of licensed beds ranged from 12 to 1000, with a mean of
203 beds, and the number of critical care beds ranged from 0 to 150, with a mean of 24
beds. The number of critical care units ranged from 0 to 6, with a mean of 1.73. Critical
care units included mostly medical (25.7%), surgical (21.0%), mixed medical/surgical
(67.6%), and/or cardiac (30.5%), with pediatric/neonatal (9.5%), respiratory (8.6%),
trauma (8.6%), and burn units (1.9%) also represented in the sample.
Sizable portions of the survey respondents did not know their hospital’s annual
discharges (33.3%), case mix index/CMI (88.6%), or annual antimicrobial expenditures
(86.7%). However, a large majority of survey respondents (82.9%) did report that they
had access to their hospital’s antibiogram (laboratory-provided assessment of the level of
antimicrobial resistance of isolated microorganisms). Two-thirds of survey respondents
(66.7%) reported that their hospital had ID physician service (either on a consultative
basis or as actual hospital medical staff). Almost two-thirds (60.0%) reported having a
pharmacist assigned to manage antimicrobial prescriptions (either an ID pharmacist or
non-specialized clinical pharmacist).
Prevalence of antimicrobial stewardship strategy use
The distribution of the number of antimicrobial stewardship strategies in use in
the overall sample is shown in Figure 3. The distribution was relatively symmetrical with
a slight left skew. All respondents (100%) reported the use of at least one antimicrobial
stewardship strategy. The number of strategies in use ranged from 1-10, and the mean
number of strategies used was 6.11. The mean number of strategies in use, by state and
by region, is shown in Tables 3 and 4, respectively. Idaho and Alaska reported the
highest number of strategies used, at 9.00 and 8.00, respectively; however, these two
16

states had only one respondent each. States with means of 7.00 to 7.67 strategies used
included Arizona, Washington, Texas, Montana, and South Dakota. States with means of
6.00 to 6.70 strategies used included California, Oklahoma, Nebraska, Colorado, and
Hawaii. The latter had only one respondent. States with means of 5.37 to 5.67 strategies
used included North Dakota, Utah, and Nevada. The states with the lowest means of
strategies used were Wyoming (4.58) and Oregon (4.33).

25.0

% of Respondents

20.0
15.0
10.0
5.0
0.0
1

2

3

4
5
6
7
8
Number of AS strategies used

9

10

Figure 3. Number of antimicrobial stewardship strategies in use per hospital.
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Table 3. Mean number of antimicrobial stewardship strategies in use, by state.
# of
Standard
State
hospitals Mean
Deviation
ID
1
*
*
AK
1
*
*
AZ
3
7.67
1.15
WA
3
7.67
1.15
TX
9
7.11
1.90
MT
3
7.00
2.00
SD
2
7.00
1.41
CA
23
6.70
1.43
OK
3
6.67
2.31
NE
8
6.13
1.46
CO
5
6.00
0.00
HI
1
*
*
ND
3
5.67
3.51
UT
6
5.67
1.63
NV
19
5.37
1.50
WY
12
4.58
2.15
OR
3
4.33
1.15
Total
105
6.11
1.82
*Unable to calculate mean/standard deviation

Table 4. Mean number of antimicrobial stewardship strategies in use, by region.

Region
VI
VII
VIII
IX
X
Total

N
12
8
31
46
8
105

Mean
7.00
6.13
5.52
6.20
6.63
6.11

Standard
Deviation
1.91
1.46
2.01
1.59
2.13
1.82

The proportion of respondents reporting the use of at least one antimicrobial
stewardship strategy was equal between regions, and the number of antimicrobial
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stewardship strategies in use did not significantly differ by region either (p=0.139), as
determined by ANOVA.
Types of stewardship strategies in use
The percentage of survey respondents using each antimicrobial stewardship
strategy is listed in Table 5. Greater than three-quarters of survey respondents reported
using dose optimization (93.3%), streamlining/de-escalation (83.8%), education of
prescribers (79.0%), and/or antimicrobial combination therapy (79.0%). About twothirds of respondents reported the use of intravenous-to-oral (IV-to-PO) conversion plans
(69.5%) and evidence-based guidelines and pathways (64.8%). Less than half of survey
respondents reported the use of prospective audit (47.6%), antimicrobial order forms
(42.9%), and formulary restriction (40.0%). The least-used antimicrobial stewardship
strategy was antimicrobial cycling (11.4%).

Table 5. Percentage of respondents using each antimicrobial stewardship strategy.
AS strategy*
Dose optimization
Streamlining/de-escalation
Prescriber education
Combination therapy
IV-to-PO conversion plan
Guidelines & pathways
Prospective audit
Order forms
Formulary restriction
Cycling
*Not mutually exclusive

No. (%) of respondents
98 (93.3%)
88 (83.8%)
83 (79.0%)
83 (79.0%)
73 (69.5%)
68 (64.8%)
50 (47.6%)
45 (42.9%)
42 (40.0%)
12 (11.4%)
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Regarding the results in the use of each particular antimicrobial stewardship
strategy, also determined by ANOVA, the only significant differences found between
regions was for formulary restriction with pre-authorization and antimicrobial order
forms (Table 6).

Table 6. Differences in use of individual antimicrobial stewardship strategies,
between regions.
AS strategy
Education of prescribers
Formulary restriction
Prospective audit
Guidelines/pathways
Cycling
Order form
Combination therapy
Streamlining/de-escalation
Dose optimization
IV-to-PO conversion
*Significant at p<0.05

p-value
0.374
0.009*
0.239
0.938
0.844
0.041*
0.171
0.129
0.428
0.081

Summary data of formulary restriction and antimicrobial order form use by region are
shown in Tables 7 and 8, respectively. There was a large range in the use of formulary
restriction between regions, with 83.33% of respondents from Region VI reporting the
use of formulary restriction at their facilities, while only 25.81% of respondents from
Region VIII indicated use of formulary restriction. Similarly, there was also a large
range in the use of antimicrobial order forms betweens regions, with 75.00% of
respondents from Region VII reporting the use of order forms at their facilities, while
only 22.58% of respondents from Region VIII indicated use of order forms. The results
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of each post-hoc comparison between regions for formulary restriction and antimicrobial
order form use are shown in Table 9 and 10, respectively.

Table 7. Formulary restriction use, by region.
Region (N)
VI (12)
VII (8)
X (8)
IX (46)
VIII (31)
Total (105)

No. (%) using formulary
restriction
10 (83.33%)
4 (50.00%)
4 (50.00%)
16 (34.78%)
8 (25.81%)
42 (40.00%)

Table 8. Antimicrobial order form use, by region.
Region (N)
VII (8)
VI (12)
IX (46)
X (8)
VIII (31)
Total (105)

No. (%) using antimicrobial
order forms
6 (75.00)%
6 (50.00%)
23 (50.00%)
3 (37.50%)
7 (22.58)%
45 (42.86%)
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Table 9. Differences in use of formulary restriction, between regions.
Comparison
VI
vs.
VII
vs.
VIII
vs.
IX
vs.
X
VII
vs.
VIII
vs.
IX
vs.
X
VIII
vs.
IX
vs.
X
IX
vs.
X
*Significant at p<0.05

Mean
difference
0.33
0.58
0.49
0.33
0.24
0.15
0.00
-0.09
-0.24
-0.15

p-value
0.123
0.000*
0.002*
0.123
0.197
0.399
1.000
0.413
0.197
0.399

Table 10. Differences in use of order forms, between regions.
Comparison
VI
vs.
VII
vs.
VIII
vs.
IX
vs.
X
VII
vs.
VIII
vs.
IX
vs.
X
VIII
vs.
IX
vs.
X
IX
vs.
X
*Significant at p<0.05

Mean
difference p-value
-0.25
0.259
0.27
0.098
0.00
1.000
0.13
0.572
0.52
0.007*
0.25
0.179
0.38
0.123
-0.27
0.016*
-0.15
0.438
0.13
0.501

Barriers to formal antimicrobial stewardship programs
Although all 105 survey respondents reported the use of at least one antimicrobial
stewardship strategy at their hospital, only 51 respondents (48.6%) reported the presence
of a formal antimicrobial stewardship program (ASP) at their facility (Appendix E). Two
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respondents (1.9%) indicated that they were uncertain if their hospital had a formal ASP.
Of the respondents who reported not having a formal ASP (52, or 49.5%), the barriers
indicated for not having one are listed in Table 11. Half of the respondents noted that
staffing constraints were a barrier. Over one-third indicated that inadequate
administration (38.5%) and/or prescriber support (36.5%) or not having antimicrobial
stewardship as a clinical priority (34.6%) were barriers. About a quarter of respondents
indicated the barriers of inadequate information technology support (26.9%) and/or lack
of funding (25%). A smaller percentage of respondents (11.5% to 21.2%) noted the
barriers to establishing a formal ASP as the lack of program leadership, not previously
considering a formal ASP, not needing a formal ASP, and the possibility that a formal
ASP would damage relationships with prescribers.

Table 11. Reasons listed for not having a formal antimicrobial stewardship
program (ASP).
Barriers to establishing a formal ASP*
Staffing constraints
Inadequate administration support
Inadequate prescriber support
Not a clinical priority
Inadequate information technology support
Lack of funding
No one has volunteered to lead
Not previously considered
No need for a formal program
Would damage relationships with prescribers
*Not mutually exclusive
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Number (%)
26 (50.0%)
20 (38.5%)
19 (36.5%)
18 (34.6%)
14 (26.9%)
13 (25.0%)
11 (21.2%)
9 (17.3%)
7 (13.5%)
6 (11.5%)

The frequency of each of the ten reported barriers to establishing a formal ASP did not
significantly differ by region, as analyzed by ANOVA (see Table 12 for results).

Table 12. Differences in reported barriers to implementation of a formal ASP,
between regions.
Barrier to ASP
Lacking of funding
Staffing constraints
No leader has volunteered
Inadequate prescriber
support
Inadequate admin support
Not a clinical priority
Inadequate info tech
support
Damaging MD relations
Not previously considered
No need for formal ASP

p-value
0.697
0.951
0.820
0.998
0.732
0.574
0.719
0.799
0.764
0.355

Similarly, the total number of reported barriers to formal ASP establishment (with a
possible range of 1 to 10) did not significantly differ between regions (p=0.626).
Factors associated with the number of AS strategies in use
For this study, it was found that the number of antimicrobial stewardship
strategies in use (from 1 to 10) strongly and significantly correlated with the number of
antimicrobial stewardship successes reported (from 1 to 7) (Spearman’s rho = +0.500;
p<0.001). The seven antimicrobial stewardship successes offered as choices in the
survey were:
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1.
2.
3.
4.
5.
6.
7.

Improved patient outcomes
Reduced infection rates
Decreased antimicrobial costs
Decreased antimicrobial doses prescribed
Change in antimicrobial resistance patterns/Increased antimicrobial sensitivities
Reduced adverse medication events
Decreased secondary infections

Univariate analyses of the association between each of 71 categorical and continuous
survey respondent/hospital characteristics and the number of antimicrobial stewardship
strategies in use yielded 53 significant factors with a p-value of less than 0.1. The results
of all 71 analyses are shown in Appendix F.
Of the 53 significant factors, the 37 factors (indicated by ^ in Appendix F) that
could be considered “controllable”, or open to change with influence, were included in
the initial regression model. Multiple regression analysis via forward method was
performed, resulting in 6 models with adjusted R-squares ranging from 0.296 for Model 1
with one factor (presence of formal AS program) up to a maximum of 0.538 for Model 6
with six factors (presence of formal AS program, use of clinical decision support, use of
computer monitoring of antimicrobial prescriptions, presence of an antibiogram, absence
of support from other departments, and having support from the infection
prevention/control department). Beta coefficients for Model 6 are listed in Table 13.
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Table 13. Regression model for prediction of number of antimicrobial stewardship
strategies used.
Coefficients
Unstandardized
Coefficients
Model
6 (Constant)
AS program
Clinical decision
support for
antimicrobial
prescription/dosing
Antibiogram
Computer-assisted
monitoring of
antimicrobial
prescriptions
No support from
other
departments/comm
ittees
Infection
Prevention/Control

B
5.747

Std.
Error
0.703

1.354

0.287

0.989

95.0%
Confidence
Interval for B

Standardized
Coefficients
t
8.176

Sig.
0.000

Lower
Bound
4.350

Upper
Bound
7.143

0.382

4.716

0.000

0.784

1.925

0.320

0.230

3.093

0.003

0.354

1.624

1.081

0.358

0.232

3.020

0.003

0.370

1.792

0.765

0.325

0.178

2.357

0.021

0.120

1.410

-2.365

0.712

-0.367

-3.319

0.001

-3.780

-0.949

-1.462

0.648

-0.251

-2.257

0.026

-2.749

-0.175

Beta

The mathematical expression for Model 6 is shown below. All of the six included
variables are dichotomous and, thus, to be coded as 0 or 1.
Number of AS strategies in use = 5.747 + 1.354 (presence of formal AS program)
+ 0.989 (presence of clinical decision support)
+ 1.081 (presence of antibiogram)
+ 0.765 (presence of computer-assisted
prescription monitoring)
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– 2.365 (absence of support from other
departments/committees)
– 1.462 (presence of support from infection
prevention/control department)

Positive predictors of the number of antimicrobial stewardship strategies in use, in order
of decreasing strength, included the presence of a formal antimicrobial stewardship
program (with a beta coefficient of 1.354), presence of an antibiogram (1.081), presence
of clinical decision support to assist prescribers with appropriate antimicrobial selection
(0.989), and presence of computer-assisted monitoring of antimicrobial prescriptions
(0.765) (Table 15). Negative predictors of the number of strategies included the absence
of support from other departments or committees within the hospital (-2.365) and the
presence of support from the infection prevention and control department, specifically (1.462). As an example of how to apply the model, a hospital would be expected to be
using 5.747 strategies to begin with. If that hospital does not have a formal ASP(+0), but
uses clinical decision support (+0.989), receives an antibiogram (+1.081), does not utilize
computer-assisted prescription monitoring (+0), and has the support of other departments
(+0), one of which is their infection control department (-1.462), one would be expect
that hospital to be using 6.355 antimicrobial stewardship strategies.

Discussion
The null hypotheses for Research Questions 1 and 3 were not rejected by the
results of the analyses. The number of respondents engaging in at least one antimicrobial
stewardship strategy and the reported barriers to the establishment of formal
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antimicrobial stewardship programs were the same between regions. The null hypothesis
for Research Question 2 was rejected at p=0.009 and p=0.041 for two of the
antimicrobial stewardship strategies (formulary restriction and antimicrobial order forms,
respectively) but was not rejected for the other eight strategies. The null hypothesis for
Research Question 4 was rejected at p<0.05 for 46 factors (with a range of p<0.001
through p=0.046, depending on the factor tested). Although the practice of eight of the
antimicrobial stewardship strategies did not vary between regions, the frequency with
which the strategies of formulary restriction and antimicrobial order forms are practiced
did differ between regions, and there was at least one factor found to be associated with
the number of antimicrobial stewardship strategies in place at a facility.
The present survey’s estimated response rate of 9-11% may seem low compared
to the 53% and 39% response rates for the two single-state antimicrobial stewardship
surveys in the literature (Trivedi et al., 2013; Doron et al., 2013); however, our response
rate is comparable to the 10% and 7% response rates for the two national (i.e., multistate) surveys in the literature (Pope et al., 2009; Abbo et al., 2013). Our sample size also
fell within the range of the four previously published surveys (105 vs. 82-406). Our
survey respondents were more heavily weighted with infection control professionals
(57.1% vs. 20-37%) and less weighted with pharmacists (24.8% vs. 41-80%) and
physicians (13.3% vs. 20-28%) than the previous surveys, but were similar in proportion
with regard to “other” disciplines, such as administrators, microbiologists, and healthcare
epidemiologists (4.8% vs. 5-5.1%). Most notably, our sample included a sizable portion
of smaller, rural critical access hospitals (27.6%) in addition to general acute care
hospitals (59.0%), owing to the size and geography of the states surveyed.
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The goal of the present study was to describe the antimicrobial stewardship
practices in a sample of hospitals in the western United States and determine the factors
associated with the number of antimicrobial stewardship strategies in use at a facility, as
opposed to factors associated with the presence of a formal antimicrobial stewardship
program, which has been the focus of previous studies (Pope et al., 2009; Abbo et al.,
2013; Doron et al., 2013; Trivedi et al., 2013). Similar to the previous surveys, the
prevalence of the use of antimicrobial stewardship strategies recommended in the 2007
IDSA/SHEA Guidelines in this study (100%) was roughly double the prevalence of
formally established antimicrobial stewardship programs (48.6%). Our results also show
that hospitals in the western U.S. are actively engaged in antimicrobial stewardship
activities despite reporting numerous barriers to the establishment of formalized
programs, such as staffing constraints and lack of funding. Although California was the
only state in the sample (and is the only state in the U.S.) with legislation mandating the
more judicious use of antimicrobials (CA SB739), the results from this survey indicate
that hospitals in other states throughout the west are also engaging in antimicrobial
stewardship practices, without the necessity for a legislative mandate. However, the
establishment of regulatory mechanisms and reimbursement deductions such as those
being implemented by The Joint Commission (TJC) and CMS will certainly not hurt the
future growth of antimicrobial stewardship practices in healthcare facilities.
The fact that the surveyed regions did not significantly differ in the reported use
of eight of the ten distinguishable antimicrobial stewardship strategies may demonstrate
the success of educational outreach efforts and communications from various infectious
disease authorities such as the CDC and the IDSA, as well as the degree to which hospital
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staff regularly review and implement best antimicrobial use practices from the scientific
literature. The significant differences between regions in the reported use of formulary
restriction and antimicrobial order forms cannot be easily explained and is a topic for
further research, but it can be hypothesized that the regulations established by state
payers such as Medicaid may account for these differences.
While the primary goal of this study was to examine the factors associated with
the number of practices in place, the prevalence for some of the antimicrobial
stewardship strategies inquired about in this study did somewhat vary from those found
in previous surveys. The prevalence of formulary restriction was 40.0% in the present
study, similar to that in the surveys done by Pope (38%) and Trivedi (44-49%).
However, the present study’s respondents reported a higher prevalence of prescriber
education (79.0% vs. 31-69%) and a much higher prevalence of dose optimization
(93.3% vs. 22-45%) and streamlining/de-escalation (83.8% vs. 4-28%) than seen in other
studies (Pope et al., 2009; Abbo et al., 2013; Doron et al., 2013; Trivedi et al., 2013).
This increased use of these antimicrobial stewardship strategies is likely due to the
dedicated focus on antimicrobial stewardship in both the scientific literature and by
infectious diseases professional societies such as APIC, IDSA, and SHEA, as the primary
means with which to combat the increasing problem of antimicrobial resistance. The fact
that CMS and other healthcare payers are implementing reimbursement reductions based
on the presence of infections within the hospital setting certainly may also be playing a
large role in promoting the greater use of antimicrobial stewardship strategies.
While the totality of our sample reported the use of at least one antimicrobial
stewardship strategy at their hospital, having a formal antimicrobial stewardship program
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(ASP) was found to be significantly associated with the implementation of a larger
number of strategies, which in turn was significantly related to a larger number of
perceived “successes” reported by respondents. Thus, the barriers to the development of
formal ASPs deserve exploration. Barriers to the establishment of formal ASPs are still
present, and all barriers examined in this study were found to be universal across the
sampled states. The prevalence levels of some barriers in our study were comparable to
those from previous surveys, such as staffing constraints (50% vs. 47-56%, respectively)
and low prioritization (34.6% vs. 22-44%). However, some barriers had greater
prevalence in our study compared to previous surveys, notably inadequate prescriber
support (36.5% vs. 18-32%, respectively), inadequate administration support (38.5% vs.
14-18%), and inadequate information technology support (26.9% vs. 19%). On a more
positive note, some barriers showed a lower prevalence in comparison to previous
surveys, such as lack of funding (25.0% vs. 36-69%) and lack of a willing leader for the
program (21.2% vs. 42%). There were also a lower percentage of respondents in this
study (compared to other studies) who indicated that their facility had never considered
having a formal ASP (17.3% vs. 24-37%) (Pope et al., 2009; Abbo et al., 2013; Doron et
al., 2013; Trivedi et al., 2013).
As a counter to the funding barrier, there is ever-growing evidence in the
literature that ASPs can be self-funding through the cost savings they achieve (Pope et
al., 2009; Goff et al., 2011). Partnerships between acute care hospitals and the rural
critical access hospitals in the surrounding regions, as well as the involvement of quality
and patient safety organizations such as the CMS QIOs, can be instrumental in increasing
the prevalence of ASPs and the use of multiple antimicrobial stewardship strategies.
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However, the more difficult task of overcoming inadequate institutional commitment to
antimicrobial stewardship remains, and obtaining this support will be essential for the
more widespread establishment of ASPs.
When evaluating what factors are associated with the number of antimicrobial
strategies in use, the author felt it useful to differentiate between those factors deemed to
be “unchangeable” – such as hospital classification or number of critical care units – and
those that could be considered to be more “controllable”, or subject to influence – such as
the presence of an antibiogram or support for stewardship by other departments and/or
disciplines. While it is certainly informative to posit the baseline number of
antimicrobial stewardship strategies that might be expected for a facility based on certain
hospital characteristics, it is perhaps even more important to predict the changes in the
number of strategies that may occur in association with factors that are more open to
influence. Previous studies have examined factors associated with the presence of an
ASP (Doron et al., 2013; Trivedi et al., 2013), but none have looked at the factors
associated with the actual number of antimicrobial stewardship strategies in use without
regard for whether a formalized program was present.
In the proposed model of “controllable” predictors in the present study, the
presence of a formal ASP is actually one of the significant positive predictors of the
number of stewardship strategies in use at a hospital. The other predictors of the number
of stewardship strategies in place at a hospital – the positive association with use of an
antibiogram, use of clinical decision support, and use of computer-assisted monitoring of
prescriptions, as well as the negative association with the absence of support from other
departments -- are similarly intuitive. However, the fact that the involvement of the
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infection control department was a negative predictor for the number of stewardship
strategies appears counter-intuitive. This quizzical association might have its origins in
the slightly different focal points of infection control versus antimicrobial stewardship.
For infection control, the focus is on preventing initial infection and preventing the
spread of infection that is already present; whereas, for antimicrobial stewardship, the
focus is on the prevention of antimicrobial resistance through the appropriate use of
antibiotics in those already infected. Regardless, the practicality of this predictive model
should be underscored, as it represents one of the first attempts to provide evidencedriven direction to the many hospitals that are seeking to combat the public health issue
of antimicrobial resistance within their facilities. The utility of the model lies in
application of the six factors in order to develop the infrastructure from which the
practice of antimicrobial stewardship strategies can be more effectively supported.
The results of the present survey may not be generalizable to other U.S. hospitals
due to response bias, because the sample was drawn from QIO, SHEA, and APIC
associates; thus, the respondents might have been more likely to respond to a query
regarding antimicrobial stewardship. Another possible limitation of the survey was that
there was only one spokesperson for each hospital and their opinion of the antimicrobial
stewardship practices may have been inaccurate; however, in most cases, by virtue of
their position/discipline at their facility, this representative would have had knowledge of
the information required to answer the survey questions. The survey received a fair
degree of participation from some states, but no or very little participation from others,
representing only 6.4% of the total number of hospitals in participating states.
Additionally, this total number of hospitals was gleaned from the CMS Hospital Compare
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hospital database, which identifies only hospitals that are licensed and seek
reimbursement from Medicare. Other limitations of this study include the self-report bias
usually associated with surveys and the possibility of duplicate hospitals reporting
because respondents were not required to provide facility identifiers beyond state of
location and various hospital characteristics such as bed size. Nevertheless, this study did
include hospitals that were varied in their characteristics, confirmed the widespread
implementation of antimicrobial stewardship strategies, and pointed at the challenges and
successes that can be utilized to guide the further development of antimicrobial
stewardship in facilities that are struggling with MDROs.
In conclusion, the results of this survey of antimicrobial stewardship practices in
the Western United States have demonstrated the widespread use of stewardship
strategies in general, as well as an increase from previous surveys in the reported usage of
dose optimization, streamlining and de-escalation, and prescriber education in particular.
Similar to previous surveys, there is a continuing struggle with the development of formal
antimicrobial stewardship programs, although the barriers appear to have changed from
lack of funding and program leadership to lack of administrator and prescriber support
for antimicrobial stewardship. Importantly, this survey identified several “controllable”
predictors of antimicrobial stewardship success besides having a formal program –
namely, the presence of an antibiogram and the necessity of support from other
disciplines, as well as the use of information technologies such as clinical decision
support and computer-assisted monitoring of antimicrobial prescriptions. Future
directions include the delineation of which antimicrobial stewardship strategies are
associated with the greatest number of successes in terms of improved patient outcomes
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and the further stratification of the data by general acute care versus critical access
hospitals to assist in determining which strategies are most beneficial to each hospital
classification.

35

Appendix A – Antimicrobial stewardship practices survey

The School of Community Health Sciences, Department of Epidemiology and
Biostatistics, at the University of Nevada, Las Vegas, is conducting this survey to assess
current antimicrobial stewardship practices at acute care and critical access hospitals in a
sample of states in the western U.S. Please take 15 minutes to complete this survey,
whether or not you feel that your hospital uses antimicrobial stewardship strategies (you
might be surprised to find out that your hospital actually is!). This survey is best
completed by ONE professional (e.g. ID pharmacist, pharmacy director, ID physician,
medical director, or infection control professional) per hospital, even if the hospital is
part of a multi-hospital healthcare system. Responding facilities will be de-identified, and
composite results from this survey will be returned to each participant for use in the
continual development or initiation of antimicrobial stewardship efforts. THANK
YOU!!!

Q1 What is your position at your hospital?







Infectious Diseases Pharmacist (1)
Pharmacy Director (2)
Infectious Diseases Physician (3)
Medical Director (4)
Infection Control Professional (5)
Other (please specify) (6) ____________________

Q2 In which state is your hospital located? ____________________

Q3 Is your hospital part of a multi-hospital healthcare system?
 Yes (please specify how many hospitals make up the system) (1)
____________________
 No (2)
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Q4 How would you classify your hospital?





Rural/Critical Access (1)
General Acute Care (2)
Specialty Hospital (Cardiac, Rehab, etc.) (3)
Other (please specify) (4) ____________________

Q5 Is your hospital proprietary or not-for-profit?
 Proprietary (1)
 Not-for-profit (2)
 Other (please specify) (3) ____________________
Q6 Is your hospital teaching or non-teaching?





Major physician teaching (Students, Interns, Residents, Fellows) (1)
Limited physician teaching (Residents, Fellows) (2)
Non-teaching (3)
Other (please specify) (4) ____________________

Q7 What is the number of licensed beds in your hospital (without Nursery)? ________

Q8 What was your hospital’s total number of discharges last calendar year?











Less than 100 (1)
Between 101 and 500 (2)
Between 501 and 1000 (3)
Between 1001 and 2000 (4)
Between 2001 and 4000 (5)
Between 4001 and 6000 (6)
Between 6001 and 8000 (7)
Between 8001 and 10,000 (8)
Greater than 10,000 (9)
I don't know (10)

Q9 What is the number of designated critical care beds in your hospital? ______
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Q10 What type(s) of Critical Care Units does your hospital have? Check all that apply.









Mixed Medical/Surgical (1)
Medical (2)
Surgical (3)
Cardiac Care (4)
Respiratory (5)
Burn (6)
Trauma (7)
Other (please specify) (8) ____________________

Q11 If you know the average monthly case mix index (CMI) for your hospital, please
enter it here.
 CMI: (1) ____________________
 I don't know (2)
Q12 How frequently do you receive facility-specific susceptibility data (i.e.
antibiogram)?





Every 6 months (1)
Yearly (2)
Other (please specify) (3) ____________________
Don't receive facility-specific susceptibility data (4)

Q13 Please specify the characteristics of the facility-specific antibiogram. Check all that
apply.






Provides unit-specific data also (i.e., ICU) (1)
Limited to organisms with >30 pathogens per cycle (2)
Cumulative numbers provided for organisms with <30 pathogens per cycle (3)
None of these characteristics (4)
Don't receive a facility-specific antibiogram (5)
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Q14 Does your microbiology laboratory provide individualized patient-specific
susceptibility data in addition to culture results?
 Yes (1)
 No (2)
 I don't know (3)
Q15 Does your microbiology laboratory provide Minimum Inhibitory Concentration
(MIC) results when reporting patient-specific susceptibility data, in addition to the
classifications of Sensitive, Intermediate, Resistant?
 Yes (1)
 No (2)
 I don't know (3)
Q16 What is the total yearly antimicrobial expenditure (antibacterials and antifungals
only) at your hospital?
 Annual antimicrobial expenditure: (1) ____________________
 I don't know (2)
Q17 What percent of your hospital’s total inpatient pharmacy drug budget is represented
by antimicrobials (antibacterials and antifungals only)?







Less than 10% (1)
Between 10% and 20% (2)
Between 21% and 30% (3)
Between 31% and 50% (4)
Greater than 50% (5)
I don't know (6)

Q18 Does your hospital have an Infectious Disease specialty physician-based service?





Yes, but it is consult only (1)
Yes, the physicians are paid hospital staff (i.e., employees of hospital) (2)
No (3)
I don't know (4)
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Q19 Does your hospital have a pharmacist assigned to manage antimicrobials?





Yes, and they are board-certified in Infectious Diseases Pharmacy (1)
Yes, but they are NOT board-certified in Infectious Diseases Pharmacy (2)
No (3)
I don't know (4)

Q20 Does your hospital have an Infectious Disease specialty physician fellowship
training program?
 Yes (1)
 No (2)
 I don't know (3)
Q21 Which of the following techniques are utilized in your hospital to educate
physicians/prescribers about the appropriate prescription of antimicrobials? Check all
that apply.








Newsletter/Written guidelines (1)
Email alerts (2)
Grand Rounds for students/house staff (3)
Conference presentations (4)
Webinars (5)
Other (please specify) (6) ____________________
No formal education of prescribers has been done (7)

Q22 Does your institution utilize any of the following antimicrobial restriction methods?
Check all that apply.
 Specific antimicrobials are only dispensed after approval is obtained (also known as
"formulary restriction with preauthorization") (1)
 Antimicrobials are dispensed but subject to future review with recommendations (also
known as "prospective audit with feedback and/or intervention") (2)
 Infectious Disease consult required (3)
 None (4)
 Other (please specify) (5) ____________________
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Q23 Who is responsible for providing the approval for restricted antibiotics? Check all
that apply.







Infectious Diseases physician (1)
Infectious Diseases pharmacist (2)
Infectious Diseases fellow (3)
Other (please specify) (4) ____________________
I don't know (5)
Don't utilize formulary restriction and preauthorization (6)

Q24 Who is responsible for reviewing antimicrobial prescriptions and making
recommendations? Check all that apply.







Infectious Diseases physician (1)
Infectious Diseases pharmacist (2)
Infectious Diseases fellow (3)
Other (please specify) (4) ____________________
I don't know (5)
Don't utilize prospective audit with feedback and/or intervention (6)

Q25 Does your facility have a designated group (e.g. Pharmacy &Therapeutics
committee or special subcommittee) that determines formulary restrictions?
 Yes (please specify the committee or discipline) (1) ____________________
 No (2)
 I don't know (3)
Q26 Does your hospital utilize institutional evidence-based practice guidelines and
clinical pathways that incorporate local resistance patterns when making decisions with
regard to antimicrobial prescription?
 Yes (1)
 No (2)
 I don't know (3)
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Q27 Does your hospital utilize antimicrobial cycling, or the periodic substitution of a
specific antimicrobial class for another, in order to prevent antimicrobial resistance?
 Yes (1)
 No (2)
 I don't know (3)
Q28 Does your hospital utilize antimicrobial order forms (with built-in automatic stop
orders and/or physician justification requirements) in the antimicrobial prescription
process?
 Yes (1)
 No (2)
 I don't know (3)
Q29 Does your hospital utilize antimicrobial combination therapy (use of multiple
antimicrobials) for empirical initial treatment of infections in order to increase the
breadth of coverage?
 Yes (1)
 No (2)
 I don't know (3)
Q30 Does your hospital utilize streamlining (switching to a more targeted narrowspectrum antimicrobial once an organism is identified via culture) or de-escalation
(discontinuing the empirical antimicrobial if the culture is negative)?






Yes -- both streamlining and de-escalation (1)
Yes -- streamlining only (2)
Yes -- de-escalation only (3)
No, neither streamlining nor de-escalation (4)
I don't know (5)
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Q31 Does your hospital utilize dose optimization (i.e., account for individual patient
characteristics such as age, renal function, and weight; causative organism; site of
infection; and pharmacodynamics of the drug) when prescribing antimicrobials?
 Yes (1)
 No (2)
 I don't know (3)
Q32 Does your hospital utilize a systematic plan for conversion of parenteral to oral (I.V.
to P.O.) administration of antimicrobials once a patient meets defined clinical criteria?
 Yes (1)
 No (2)
 I don't know (3)
Q33 Are you satisfied with the degree of implementation of these antimicrobial
stewardship strategies/techniques at your hospital (i.e., actual practice)?
Yes (1)

Somewhat (2)

No (3)

Formulary
restriction/Preauthorization
(1)







Prospective audit with
feedback/intervention (2)







Evidence-based guidelines
and clinical pathways (3)







Antimicrobial cycling (4)
Antimicrobial order forms
(5)













Combination therapy (6)







Streamlining/de-escalation
of therapy based on culture
results (7)







Dose optimization (8)







Parenteral to oral
conversion (9)
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Q34 Are you satisfied with the outcomes/successes obtained from the implementation of
these antimicrobial stewardship strategies/techniques at your hospital?
Yes (1)

Somewhat (2)

No (3)

Not used (4)

























Antimicrobial cycling (4)









Antimicrobial order forms
(5)









Combination therapy (6)

































Formulary
restriction/Preauthorization
(1)
Prospective audit with
feedback/intervention (2)
Evidence-based guidelines
and clinical pathways (3)

Streamlining/de-escalation
of therapy based on culture
results (7)
Dose optimization (8)
Parenteral to oral
conversion (9)

Q35 What successes have you experienced at your facility as a result of the
implementation of antimicrobial stewardship strategies? Check all that apply.












Improved patient outcomes (e.g. lower mortality, decreased length of stay) (1)
Reduced infection rates (2)
Decreased antimicrobial expenditures/costs (3)
Decreased antimicrobial doses prescribed (4)
Change in antimicrobial resistance patterns/Improved antimicrobial sensitivity (5)
Reduced adverse medication events (6)
Decreased development of secondary infections (7)
Other (please specify) (8) ____________________
Have not had success with antimicrobial stewardship strategies (9)
Not currently using any antimicrobial stewardship strategies (10)
Have not been monitoring these indicators with regard to antimicrobial stewardship
(11)
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Q36 What measures is your facility using to monitor antimicrobial use? Check all that
apply.






Antimicrobial purchasing/acquisition costs (1)
Cost of antimicrobials dispensed (2)
Number of antimicrobial doses prescribed (3)
Number of antimicrobial doses dispensed (4)
Defined daily dose (DDD) -- standardized calculation from World Health
Organization (5)
 Days of antimicrobial therapy (6)
 Other (please specify) (7) ____________________
 Not measuring antimicrobial use (8)
Q37 What measures is your facility using to monitor outcomes of antimicrobial use?
Check all that apply.







Antimicrobial resistance patterns (1)
Infection rates (2)
Patient outcomes such as mortality and length of stay (LOS) (3)
Adverse drug reactions (4)
Other (please specify) (5) ____________________
Not measuring outcomes of antimicrobial use (6)

Q38 Which microorganism is the most difficult to eradicate or control within your
hospital?











Clostridium difficile (1)
Methicillin-resistant Staphylococcus aureus (2)
Vancomycin-resistant Enterococcus (3)
Acinetobacter baumannii (4)
Carbapenem-resistant Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae)
(5)
Pseudomonas aeruginosa (6)
Proteus mirabilis (7)
Serratia marcescens (8)
Enterococcus faecium/faecalis (9)
Other (please specify) (10) ____________________
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Q48 Which microorganism is the second most difficult to eradicate or control within your
hospital?











Clostridium difficile (1)
Methicillin-resistant Staphylococcus aureus (2)
Vancomycin-resistant Enterococcus (3)
Acinetobacter baumannii (4)
Carbapenem-resistant Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae
(5)
Pseudomonas aeruginosa (6)
Proteus mirabilis (7)
Serratia marcescens (8)
Enterococcus faecium/faecalis (9)
Other (please specify) (10) ____________________

Q39 Do you have the active support of any of the following entities for antimicrobial
stewardship efforts? Check all that apply.






Hospital administration (1)
Medical staff leadership (2)
Physicians/prescribers (3)
None of these entities actively support antimicrobial stewardship (4)
I don't know (5)

Q40 Do you have the support of other hospital departments/committees for antimicrobial
stewardship efforts? Check all that apply.










Infection Prevention/Control (1)
Pharmacy & Therapeutics (2)
Quality/Performance Improvement (3)
Patient Safety (4)
Nursing Leadership (5)
Microbiology Laboratory (6)
Information Technology (7)
Other (please specify) (8) ____________________
No support from other departments/committees (9)
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Q41 Which of the following information technologies are in use at your facility? Check
all that apply.





Electronic medical records (EMRs) (1)
Computerized physician order entry (CPOE) (2)
Clinical decision support for antimicrobial prescription/dosing (3)
Computer-based surveillance (of hospital-acquired infections, adverse medication
events, resistance patterns) (4)
 Computer-assisted monitoring of antimicrobial prescriptions (5)
 Other (please specify) (6) ____________________
 None of these (7)
Q42 Does your hospital have a formally organized and identified Antimicrobial
Stewardship Program (ASP), in addition to utilizing various antimicrobial stewardship
strategies? An ASP is typically defined as a multidisciplinary team officially recognized
by hospital administration who meets regularly for the set purpose of planning and
coordinating antimicrobial stewardship efforts to accomplish specific goals or outcomes
for the facility.
 Yes (1)
 No (2)
 I don't know (3)
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Q43 What disciplines are represented on your facility’s Antimicrobial Stewardship
Program team? Check all that apply.













Infectious Diseases Physician (1)
Other physician (2)
Infectious Diseases Pharmacist (3)
Other pharmacist (4)
Infection control professional (5)
Clinical microbiologist (6)
Hospital epidemiologist (7)
Hospital administrator (8)
Information technology specialist/Data analyst (9)
Other discipline (please specify) (10) ____________________
I don't know (11)
Team still in development, even though we have a recognized Antimicrobial
Stewardship Program (12)
 Don't have a formal Antimicrobial Stewardship Program (13)
Q44 How long has your facility’s Antimicrobial Stewardship Program been in place?







It is currently in development (1)
Less than 1 year (2)
Between 1 and 3 years (3)
Greater than 3 years (4)
I don't know (5)
Don't have a formal Antimicrobial Stewardship Program (6)
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Q45 Why doesn’t your hospital have a formally organized and identified Antimicrobial
Stewardship Program? Check all that apply.













Lack of funding (1)
Staffing constraints (2)
No one has volunteered to lead the program (3)
Insufficient physician/prescriber support of antimicrobial stewardship (4)
Insufficient administration support of antimicrobial stewardship (5)
Not high on the list of clinical priorities (6)
Inadequate information technology support (7)
Concern about damaging relationships with physicians/prescribers (8)
Organized program has not previously been considered (9)
No identified need for a formally organized program at this time (10)
Other (please specify) (11) ____________________
We have a formal Antimicrobial Stewardship Program (12)

Q46 Thank you for completing this survey! Please provide your contact information
below. This information is optional but strongly encouraged, and will be used to clarify
responses, obtain additional information, and return the blinded study results. Composite
data will be shared with participants who provide contact information in order to help
them with their practice. If you wish to receive the results of this survey and/or are
willing to be contacted with any questions or clarifications to your responses, you MUST
complete this section.
Name (1)
Email address (2)
Phone number (3)
Position/Title (4)
Associated hospital/facility (5)

Q47 Please feel free to share below any comments, concerns, or challenges in regard to
antimicrobial stewardship initiatives. Be sure to click the >> button below when you are
finished. You will then be redirected to a screen confirming that you have successfully
completed the survey. Thank you once again! If you have any immediate questions or
comments, please contact Gayle Allenback at allenbac@unlv.nevada.edu.
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Appendix B – Survey from Doron, et al., 2013

In an effort to characterize antimicrobial stewardship practices in healthcare systems, the
Division of Infectious Diseases at Tufts Medical Center is conducting this important
survey to assess the antimicrobial stewardship methods at individual hospitals. Our goal
is to characterize current antimicrobial practices and to better understand the efficacy and
success of these programs. Please take ~10 minutes to complete this national survey, the
largest of its kind to date. Note: this survey is best completed by ONE ID pharmacist,
pharmacy director, or ID physician per institution. The responding institutions will be deidentified and results from this survey will be returned to each participant for use in the
continual development or initiation of a stewardship program.
Section 1: Demographics
1. How would you best describe your position at your facility?
ID pharmacist
Pharmacy Director
ID Physician
Other (please specify)
2. How would you classify your healthcare system?
University teaching hospital.
University-affiliated teaching hospital.
Non-university teaching hospital.
Not a teaching hospital.
Rural or critical access
Acute/Rehab
3. What is the number of licensed beds in your facility?
Fewer than 100
Between 101 and 300
Between 301 and 500
More than 500
4. What is the average annual number of admissions for your healthcare facility?
Less than 1,000
Between 1,001 and 2,500
Between 2,501 and 5,000
Between 5,001 and 10,000
More than 10,000
5. What state is your institution located in?
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State: _____________

6. If you know the average monthly case mix index for your healthcare system,
please enter it here.
______________

I do not know

7. Does your facility produce a cumulative susceptibility guide (i.e. antibiogram)?
Yes
No
I don't know
8. If the answer to question 7 is yes, how frequently is your cumulative susceptibility
guide (antibiogram) produced?
Every six months
Yearly
Less than yearly
Other (please specify)
9. If the answer to question 7 is yes, what is the publication date of your current
cumulative susceptibility guide (antibiogram)?
________________
10. Would you be willing to share specific antimicrobial purchase information in the
future for additional analysis?
Yes
No
11. What is the total yearly antimicrobial expenditure (antibacterials and
antifungals only) at your institution?
___________________
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12. What percent of the total inpatient pharmacy drug budget is represented by
antimicrobials (antibacterials and antifungals only)?
Less than 10%
Between 10% and 15%
Between 16% and 25%
Greater than 26%
I do not know
13. Does your institution have an Infectious Disease consult service?
Yes, full - time.
Yes, part - time.
No.
14. If your institution has an Infectious Disease consult service, are your consultants
any of the following? ** *.
Private
Hospital - based
Combination of private and hospital based
Other (please specify)
15. Does your institution have a pharmacist dedicated to the management of
antimicrobials?
Yes
No
I don't know
16. Does your institution have an antimicrobial stewardship program?
Yes
No
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Section 2: Institutions with an Antimicrobial Stewardship Program
1. If you have an antimicrobial stewardship team at your facility, who comprises it?
Check all that apply.
Infectious Disease Physician(s)
Infectious Disease Pharmacist(s)
Clinical Microbiologist
Information system specialist
Infection control professional
Hospital Epidemiologist
We have no formal "team"
Other (please specify)
2. How long ago was the stewardship program put in place?
It is in development
It is just starting
Less than 1 year ago
1 - 3 years ago
Greater than 3 years ago
3. Is your program utilized for adults, pediatrics, or both?
Adults only
Pediatrics only
Both adults and pediatrics
4. Which of the following educational techniques are used to educate prescribers
about appropriate prescription of antimicrobials? Check all that apply.
Newsletter
Email
Grand Rounds
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Conferences
None
Other (please specify)
5. Does your institution have an ID fellowship program?
Yes
No
6. If the answer to question 4 is yes, what is the level of involvement of the ID fellow
in the antimicrobial stewardship program?
The ID fellow approves restricted antimicrobials
The ID fellow approves restricted antimicrobials at certain times only, e.g. nights or
weekends
The ID fellow does not approve restricted antimicrobials
Other (please specify)
7. Does your institution utilize any of the following restriction methods? Check all
that apply.
A "front end" approach in which specific antimicrobials are only dispensed after approval
is obtained.
A "back end" approach in which antimicrobials are prescribed but are subject to
prospective audit.
Automatic stop orders
ID Consult required
Verbal approval required (telephone or face to face)
Other (please specify)
8. If a "front end" approach is used, who is responsible for providing the approval
for restricted antibiotics? Check all that apply.
Physician on the Antimicrobial Stewardship team
ID Pharmacist
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ID Fellow
Other (please specify)
9. Does your institution have a specific group that approves formulary restrictions?
No
I do not know.
Yes (please specify)
10. Which of the following antimicrobial stewardship techniques are utilized by
your institution? Check all that apply.
Guidelines and Clinical Pathways
Antimicrobial cycling
Antimicrobial order forms
Streamlining or de - escalation of therapy
Dose optimization
Parenteral to oral conversion
Closed Formulary
None
Other (please specify)
11. Are you satisfied with the degree to which clinicians at your institution
streamline or de - escalate therapy based on culture data?
Yes
No Please explain:
12. Are any of the following medications or medication classes on formulary at your
institution? Check all that apply.
Piperacillin - Tazobactam Ticarcillin- Clavulanate Ampicillin- Sulbactam Ertapenem
Meropenem Imipenem Doripenem Moxifloxacin Levofloxacin Ciprofloxacin
Gatifloxacin Cefepime Ceftazidime Ceftriaxone Cefotaxime Cefoxitin Cefazolin
Tigecycline Vancomycin Polymyxin E (Colistin) Amphotericin B Products Daptomycin
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Linezolid Fluconazole Voriconzaole Posaconazole Micafungin Caspofungin
Anidulafungin Other (please specify)
13. Are there any restrictions on the following medications or medication classes?
Check all that apply.
Check Restricted by time, Restricted by provider, ID consult required, Other restrictions
for the following:
Piperacillin - Tazobactam Ticarcillin - Clavulanate Ampicillin - Sulbactam Ertapenem
Meropenem Imipenem Doripenem Moxifloxacin Levofloxacin Ciprofloxacin
Gatifloxacin Cefepime Ceftazidime Ceftriaxone Cefotaxime Cefoxitin Cefazolin
Tigecycline Vancomycin Polymyxin E (Colistin) Amphotericin B Products Daptomycin
Linezolid Fluconazole Voriconzaole Posaconazole Micafungin Caspofungin
Anidulafungin
Please describe other restriction methods or agents that are not on this list
14. What is your perception of the extent to which physicians at your institution
agree with the restrictions on antimicrobials?
The vast majority agree.
A small majority agree.
The physicians are neutral.
A small majority disagree.
The vast majority disagree.
I do not know.
15. How does your institution measure the effectiveness of the antimicrobial
stewardship program? Check all that apply.
Antimicrobial expenditures
Antimicrobial resistance
Frequency of physicians' acceptance of the antimicrobial stewardship team's
recommendations
We do not measure the effect of the antimicrobial stewardship program
Other (please specify)
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16. What is your perception of the percent of the total number of requests for
restricted antimicrobials that is denied?
Less than 10%
Between 10% and 25%
Between 26% and 50%
More than 50%
I do not know.
17. Does your institution use proprietary or self developed software to facilitate your
antimicrobial stewardship program?
No
Self Developed
I don't know
Proprietary (please specify name of program).
18. Comments/concerns/challenges.

Section 3: Institutions without Antimicrobial Stewardship Program
1. Has your institution ever considered having an antimicrobial stewardship
program? If your answer is "yes", jump to question 3. If your answer is "no",
continue on to question 2. If your answer is "I don't know" jump to question 4.
Yes
No
I don't know
2. If your institution has not ever considered having an antimicrobial stewardship
program, why not? Check all that apply. If this question applies to you, jump to
question 4 after you complete this question.
Funding
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Staffing constraints
Insufficient medical staff buy - in
Not high on the list of priorities
Too many other things on the table
Organized program has not been proposed
Other (please specify)
3. If your institution has considered having an antimicrobial stewardship program,
why has it not been implemented? Check all that apply.
Funding
Staffing constraints
Insufficient medical staff buy - in
Not high on the list of priorities
Too many other things on the table
Organized program has not been proposed
Other (please specify)
4. If your institution implemented an antimicrobial stewardship program, would it
be utilized for adults, pediatrics, or both?
Adults only
Pediatrics only
Both adults and pediatrics
5. Does a formal education program exist to educate prescribers about the
appropriate prescription of antimicrobials?
Yes
No
I do not know
6. If the answer to question 4 is yes, which of the following educational techniques is
utilized? Check all that apply.
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Newsletter
Email
Grand Rounds
Conferences
Other (please specify)
7. Does your institution have an ID fellowship program?
Yes
No
8. Does your institution utilize any of the following restriction methods? Check all
that apply.
A "front end" approach in which specific antimicrobials are only dispensed after approval
is obtained.
A "back end" approach in which antimicrobials are prescribed but are subject to
prospective audit.
Automatic stop orders
ID consult required
Verbal approval required (telephone or face to face)
None
Other (please specify)
9. If a "front end" approach is used, who is responsible for providing the approval
for restricted antibiotics? Check all that apply.
ID Physician
ID Pharmacist
ID Fellow
Other (please specify)
10. Does your institution have a specific group that approves formulary restrictions?
No
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I don't know.
Yes (please specify)
11. Please check any techniques that your institution uses with regards to
antimicrobials.
Guidelines and Clinical Pathways
Antimicrobial cycling
Antimicrobial order forms
Streamlining or de - escalation of therapy
Dose optimization
Parenteral to oral conversion
Closed Formulary
None
Other (please specify)
12. Are you satisfied with the degree to which clinicians at your institution
streamline or de - escalate therapy based on culture data?
Yes
No Please explain:
13. Are any of the following medications or medications on formulary at your
institution? Check all that apply.
Piperacillin - Tazobactam Ticarcillin - Clavulanate Ampicillin - Sulbactam Ertapenem
Meropenem Imipenem Doripenem Moxifloxacin Levofloxacin Ciprofloxacin
Gatifloxacin Cefepime Ceftazidime Ceftriaxone Cefotaxime Cefoxitin Cefazolin
Tigecycline Vancomycin Polymyxin E (Colistin) Amphotericin B Products Daptomycin
Linezolid Fluconazole Voriconzaole Posaconazole Micafungin Caspofungin
Anidulafungin Other (please specify)
14. Are there any restrictions on the following medications or medication classes?
Check all that apply.
Please check Restricted by time, Restricted by provider, ID consult required, Other
restrictions for the following:
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Piperacillin - Tazobactam Ticarcillin - Clavulanate Ampicillin - Sulbactam Ertapenem
Meropenem Imipenem Doripenem Moxifloxacin Levofloxacin Ciprofloxacin
Gatifloxacin Cefepime Ceftazidime Ceftriaxone Cefotaxime Cefoxitin Cefazolin
Tigecycline Vancomycin Polymyxin E (Colistin) Amphotericin B Products Daptomycin
Linezolid Fluconazole Voriconzaole Posaconazole Micafungin Caspofungin
Anidulafungin
Please describe other restriction methods or agents that are not on this list
15. What is your perception of the extent to which physicians at your institution
agree with the idea of restricting antimicrobials?
The vast majority agree.
A small majority agree.
The physicians are neutral.
A small majority disagree.
The vast majority disagree.
I do not know.

Section 4: Almost done!
1. Thank you for completing this survey! Please provide your contact information
below. This information is optional but strongly encouraged, and will be used to
clarify responses, obtain additional information, and return the blinded study
results. Data will be shared with participants who provide contact information in
order to help them with their practice. If you wish to receive the results of this
survey and/or are willing to be contacted with any questions or clarifications to your
responses, you MUST complete this section.
Name:
E- mail Address:
Phone Number:
Position/Title:
Associated Institution/Facility:
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2. Would you be interested in joining a collaboration or listserv for future discussion
of antimicrobial stewardship programs?
Yes
No
3. Are you receptive to filling out a similar follow- up questionnaire?
Yes
No
4. Please enter any comments, concerns, or challenges that you wish to share in
regards to antimicrobial stewardship initiatives. This may include any suggestions
for questions to be included or excluded on a future survey. Please be sure to click
the "done" button below when you are finished. You will then be redirected to a
screen confirming that you have successfully completed the survey. Thank you once
again!
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Appendix C -- Letter to QIO HAI staff
Dear XXXXXX,
I am doing another (but larger and more in-depth) antimicrobial stewardship web-based
survey for my thesis, and I was wondering if you can help me get the survey link
distributed to acute care and critical access hospitals in your state. Of course, I would
share the results during a future webex or meeting….Participants who provide an email
address (which is optional) will receive a compilation of useful antimicrobial stewardship
literature as well as the aggregated survey results.
Here is the text I have been using in the distribution emails:
The School of Community Health Sciences, Department of Epidemiology and
Biostatistics, at the University of Nevada, Las Vegas, is conducting a survey to assess
current antimicrobial stewardship practices at acute care and critical access hospitals in
a sample of states that have been previously under-represented in the Antimicrobial
Stewardship literature.
Please take 20 minutes to complete this survey, whether or not you feel that your hospital
uses antimicrobial stewardship strategies (you might be surprised to find out that your
hospital actually is!). This survey is best completed by ONE professional (e.g. ID
pharmacist, pharmacy director, ID physician, medical director, or infection control
professional) per hospital, even if the hospital is part of a multi-hospital healthcare
system.
Responding facilities will be de-identified, and composite results from this survey, as well
as other potentially useful Antimicrobial Stewardship literature, will be shared with each
participant for use in the continual development or initiation of antimicrobial
stewardship efforts. THANK YOU!!!
Click on the link below to take the survey: DUE DATE: FEBRUARY 14, 2014
https://unlvhospitality.qualtrics.com//SE/?SID=SV_2aFXom8JDqw6swB
Let me know if you can help out, or have other suggestions… Thank you!
Gayle Allenback, MS
Infection Prevention Analyst
Valley Health System
gayle.allenback@uhsinc.com
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Appendix D – Letter to APIC/SHEA members
As a fellow APIC/SHEA member, I am requesting your assistance with the completion of
a web-based Antimicrobial Stewardship practices questionnaire that I have designed for
the thesis requirement of my MPH degree, in order to assess current Antimicrobial
Stewardship practices at acute care and critical access hospitals in western states that
have been previously under-represented in the Antimicrobial Stewardship literature.
Please take a quick 15 minutes to complete this survey, whether or not your hospital uses
antimicrobial stewardship strategies. Many thanks!
Copy and paste the URL below to take the survey:
DUE DATE: MARCH 7, 2014
https://unlvhospitality.qualtrics.com//SE/?SID=SV_2aFXom8JDqw6swB
Gayle Allenback, MS
Infection Prevention Analyst – Valley Health System, Las Vegas, NV
MPH Graduate Student – University of Nevada, Las Vegas
gayle.allenback@uhsinc.com
allenbac@unlv.nevada.edu
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Appendix E -- Characteristics of survey respondents

Characteristic
No. of respondents
Discipline of respondents
Infection Control Professional
Pharmacy Director
Infectious Diseases Physician
Infectious Diseases Pharmacist
Other Pharmacist
Other Discipline
Medical Director
Member of multi-hospital healthcare system
Yes
No
Hospital classification
General acute care
Rural/critical access
Specialty (Cardiac, Rehab, etc.)
Other
Hospital profit status
Not-for-profit
Proprietary
Hospital teaching status
Non-teaching
Major or minor physician/nurse teaching
Number of licensed beds
Number of annual discharges
Between 101 and 500
Between 501 and 1000
Between 1001 and 2000
Between 2001 and 4000
Between 6001 and 8000
Between 8001 and 10,000
Greater than 10,000
I don't know
Number of critical care beds
Types of critical care units*
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No. (%) of survey
respondents
105 (100%)
60 (57.1%)
14 (13.3%)
12 (11.4%)
7 (6.7%)
5 (4.8%)
5 (4.8%)
2 (1.9%)
62 (59.0%)
43 (41.0%)
62 (59.0%)
29 (27.6%)
10 (9.5%)
4 (3.8%)
72 (68.6%)
32 (30.5%)
55 (52.4%)
50 (47.6%)
Range 12 - 1000, Mean 203
14 (13.3%)
6 (5.7%)
4 (3.8%)
12 (11.4%)
6 (5.7%)
2 (1.9%)
22 (21.0%)
35 (33.3%)
Range 0 -150, Mean 24

Characteristic
Mixed medical/surgical
Cardiac care
Medical
Surgical
Pediatric/neonatal
Respiratory
Trauma
Burn
Number of critical care units
Knowledge of average monthly case mix index
(CMI)
Yes
No
Receive an antibiogram (ABG)
Yes
No
Knowledge of annual antimicrobial expenditures
Yes
No
Have Infectious Diseases physician service
Yes
No
Have pharmacist assigned to manage antimicrobials
Yes
No
Have a formal antimicrobial stewardship program (ASP)
Yes
No
I don't know
* Not mutually exclusive

66

No. (%) of survey
respondents
71 (67.6%)
32 (30.5%)
27 (25.7%)
22 (21.0%)
10 (9.5%)
9 (8.6%)
9 (8.6%)
2 (1.9%)
Range 0 - 6, Mean 1.73

12 (11.4%)
93 (88.6%)
87 (82.9%)
18 (17.1%)
14 (13.3%)
91 (86.7%)
70 (66.7%)
35 (33.3%)
63 (60.0%)
38 (36.2%)
51 (48.6%)
52 (49.5%)
2 (1.9%)

Appendix F -- Results of univariate analyses of 71 factors vs. number of
antimicrobial stewardship strategies used

Categorical variables (n=63)
Region
Discipline of respondent
Multi-hospital system membership
Hospital classification (4 categories)
Acute care vs. Critical access
Profit status
Teaching status
Number of annual discharges
Presence of Mixed Medical/Surgical CC unit
Presence of Medical CC unit
Presence of Surgical CC unit
Presence of Cardiac CC unit
Presence of Respiratory CC unit
Presence of Burn CC unit
Presence of Trauma CC unit
Presence of Pediatric/Neonatal CC unit
Knowledge of case mix index (CMI)
^Receive antibiogram (ABG)
Frequency of ABG
^ABG provides unit-specific data
^ABG cumulative for isolates <30
^ABG provides patient-specific data
^Lab provides minimum inhibitory concentrations (MICs)
^Knowledge of annual antimicrobial expenditures
Percent of pharmacy budget that are antimicrobials
Knowledge of percent of pharmacy budget
^ID physician service present
^Presence of pharmacist dedicated to antimicrobials
^Presence of ID fellowship program
^Measurement of antimicrobial purchasing costs
^Measurement of cost of antimicrobial dispensed
^Measurement of # antimicrobial doses prescribed
^Measurement of #antimicrobial doses dispensed
^Measurement of defined daily dose
^Measurement of days of antimicrobial therapy
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Significance level
0.139
0.287
0.001*
0.005*
0.001*
0.202
0.003*
0.046*
0.174
0.276
0.041*
0.786
0.708
0.140
0.007*
0.003*
0.916
<0.001*
0.146
0.006*
0.093*
0.086*
0.034*
0.072*
0.362
0.759
<0.001*
<0.001*
0.059*
0.009*
0.001*
0.083*
0.001*
0.003*
0.002*

Categorical variables (n=63)
^Presence of antimicrobial use measures
Number of antimicrobial use measures
^Measurement of antimicrobial resistance patterns
^Measurement of infection rates
^Measurement of patient outcomes
^Measurement of adverse reactions
Number of antimicrobial outcome measures
^Presence of antimicrobial outcome measures
Most difficult microorganism to control
^Support of hospital administration
^Support of medical staff leadership
^Support of prescribers
Number of three main supports
^Support of infection control dept.
^Support of pharmacy dept.
^Support of quality/performance improvement dept.
Support of patient safety dept.
Support of nursing leadership
^Support of microbiology laboratory dept.
Support of information technology dept.
^Presence of support of other depts.
Use of electronic medical records (EMRs)
^Use of computerized physician order entry (CPOE)
^Use of clinical decision support
^Use of computer-based surveillance
^Computer-monitoring of antimicrobial prescriptions
Number of information technology supports
^Presence of a formal AS program

Significance level
0.004*
0.001*
<0.001*
0.002*
0.041*
0.026*
0.003*
0.004*
0.090*
<0.001*
<0.001*
<0.001*
<0.001*
0.020*
0.002*
0.022*
0.174
0.584
<0.001*
0.362
<0.001*
0.572
0.039*
<0.001*
0.007*
<0.001*
<0.001*
<0.001*

Continuous variables (n=8)
Number of hospitals in system
Number of licensed beds
Number of critical care beds
Number of CC units
^Number of ABG attributes
Annual antimicrobial expenditures
^Number of committee/department supports
^Number of information technology supports
* p<0.1 (n=53)
^ Significant factors considered to be "controllable" (n=37)

Significance level
0.866
<0.001*
0.002*
0.003*
0.003*
0.501
0.001*
0.035*
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Appendix G – List of abbreviations
ABG
AK
ANOVA
APIC
AS
ASP
AZ
CA
CAH
CC
CDC
CMI
CMS
CO
CPOE
CRE
DDD
EMR
GACH
HAI
HI
ID
ID
IDSA
IV-to-PO
KS
MDRO
MIC
MRSA
MT
ND
NE
NM
NV
OK
OR
PIDS
QIO
SD
SHEA
SPSS
TJC
TX
UNLV
UT

Antibiogram
Alaska
Analysis of variance
Association for Professionals in Infection Control and Epidemiology
Antimicrobial stewardship
Antimicrobial stewardship program
Arizona
California
Critical access hospital
Critical care
Centers for Disease Control and Prevention
Case mix index
Centers for Medicare and Medicaid Services
Colorado
Computerized physician order entry
Carbapenem-Resistant Enterobacteriaceae
Defined daily dose
Electronic medical record
General acute care hospital
Healthcare-associated infection
Hawaii
Idaho
Infectious diseases
Infectious Diseases Society of America
Intravenous to oral
Kansas
Multi-drug resistant organism
Minimum inhibitory concentration
Methicillin-Resistant Staphylococcus aureus
Montana
North Dakota
Nebraska
New Mexico
Nevada
Oklahoma
Oregon
Pediatric Infectious Diseases Society
Quality Improvement Organization
South Dakota
Society for Healthcare Epidemiology of America
Statistical Package for the Social Sciences
The Joint Commission
Texas
University of Nevada, Las Vegas
Utah
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VRE
WA
WY

Vancomycin-Resistant Enterococci
Washington
Wyoming
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